Shang Hai Zheng Quan Bao·2025-11-19 18:56Core Viewpoint - The announcement indicates a significant change in the ownership structure of Ningxia Zhongke Biological Technology Co., Ltd. due to the execution of its restructuring plan, resulting in Hunan Xinhong Pharmaceutical Co., Ltd. becoming the controlling shareholder and Liu Xirong as the actual controller [1][3][5]. Group 1: Basic Situation of the Equity Change - The court has approved the restructuring plan for the company, leading to the termination of its restructuring process [2][3]. - The total share capital of the company will increase from 684,883,775 shares to 1,615,883,775 shares after a capital reserve conversion, with 931,000,000 shares being issued [3][51]. - Hunan Xinhong will hold 357,142,857 shares, representing 22.10% of the total share capital post-conversion, thus becoming the controlling shareholder [1][5]. Group 2: Changes in Shareholding Structure - Before the equity change, Shanghai Zhongneng held 200,000,000 shares (29.20% of total shares), which will decrease to 12.38% after the change [5][17]. - The actual controller will shift from Yu Jianming to Liu Xirong following the equity change [5][49]. Group 3: Subsequent Matters - Hunan Xinhong and Shanghai Zhongneng are required to prepare equity change reports as per regulations [5][6]. - The restructuring investment involves a cash payment of 400 million yuan for the shares acquired by Hunan Xinhong, with a lock-up period of 36 months [51][60].